title: Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer.
abstract: OBJECTIVE
  We analyzed the responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (NAC) and NAC combined with neoadjuvant human epidermal growth factor receptor-2 (HER2) targeted therapy (NCHTT).
  
  
  METHODS
  We retrospectively reviewed 59 patients with HER2 amplified locally advanced breast cancer among patients who were treated surgically after neoadjuvant therapy at Samsung Medical Center between 2005 and 2009. Thirty-one patients received conventional NAC and 28 patients received NCHTT. Pathologic responses were assessed according to response evaluation criteria in solid tumors (RECIST) guidelines.
  
  
  RESULTS
  Pathologic complete response (pCR) was achieved in 13 out of 28 patients treated with NCHTT and in 6 out of 31 patients treated with NAC alone (46.4% vs. 19.4%, respectively, P = 0.049). Breast conserving surgery (BCS) was more frequently performed in the NCHTT group than in the NAC only group (71.4% vs. 19.4%, P < 0.001). The 3-year recurrence-free survival (RFS) rate was 100% in the NCHTT group and 76.4% in the NAC group (P = 0.014). Together, NCHTT, type of operation (BCS vs. mastectomy) and pathologic nodal status were significant prognostic factors for RFS in univariate analysis.
  
  
  CONCLUSIONS
  We found that NCHTT produced higher pCR rates than NAC alone in locally advanced breast cancer.
authors: Department of Surgery, Seoul Medical Center, Seoul, Korea.
authors: Dong Hui
authors: DH
authors: Cho
authors: Se Kyung
authors: SK
authors: Lee
authors: Sangmin
authors: S
authors: Kim
authors: Min-Young
authors: MY
authors: Choi
authors: Seung Pil
authors: SP
authors: Jung
authors: Jeonghui
authors: J
authors: Lee
authors: Jiyoung
authors: J
authors: Kim
authors: Min Young
authors: MY
authors: Koo
authors: Soo Youn
authors: SY
authors: Bae
authors: Jung-Han
authors: JH
authors: Kim
authors: Jee Soo
authors: JS
authors: Kim
authors: Kil Won
authors: KW
authors: Ho
authors: Jeong Eon
authors: JE
authors: Lee
authors: Seok Jin
authors: SJ
authors: Nam
authors: Jung-Hyun
authors: JH
authors: Yang
keywords: Breast neoplasms; ErbB-2; Neoadjuvant therapy; Response
references: Br J Cancer. 2006 Jan 30;94(2):259-67
references: 16404427
references: J Clin Oncol. 1999 Feb;17(2):460-9
references: 10080586
references: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references: 15738535
references: Eur J Cancer Clin Oncol. 1984 Nov;20(11):1353-61
references: 6548710
references: Oncologist. 2006 Nov-Dec;11(10):1047-57
references: 17110623
references: J Natl Cancer Inst. 2004 May 19;96(10):739-49
references: 15150302
references: Cancer Cell. 2004 Apr;5(4):317-28
references: 15093539
references: Cancer Lett. 2006 Feb 8;232(2):123-38
references: 16458110
references: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references: 20180029
references: Lancet. 2010 Jan 30;375(9712):377-84
references: 20113825
references: Cancer Chemother Pharmacol. 1978;1(1):53-9
references: 373908
references: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references: 16514137
references: NCI Monogr. 1986;(1):153-9
references: 3022156
references: J Clin Oncol. 2010 Apr 20;28(12):2024-31
references: 20308670
references: J Clin Oncol. 2008 Feb 10;26(5):778-85
references: 18258986
references: Cancer Res. 2002 Oct 1;62(19):5485-8
references: 12359757
references: Int J Cancer. 2005 Sep 1;116(3):359-67
references: 15800944
references: Lancet. 2005 May 14-20;365(9472):1687-717
references: 15894097
references: Mol Cell. 2003 Sep;12(3):541-52
references: 14527402
references: J Clin Oncol. 1997 Aug;15(8):2894-904
references: 9256133
references: J Clin Oncol. 1998 Aug;16(8):2672-85
references: 9704717
references: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):281-8
references: 21293538
references: Eur J Cancer. 1980 Mar;16(3):351-6
references: 7371690
references: Nat Rev Cancer. 2009 Jul;9(7):463-75
references: 19536107